Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CRS-207 |
Synonyms | |
Therapy Description |
CRS-207 is a vaccine comprised of a live-attenuated strain of Listeria monocytogenes engineered to express human mesothelin, which induces anti-tumor immune response towards mesothelin-positive tumor cells (PMID: 22147941, PMID: 32273276, PMID: 32132105). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CRS-207 | CRS207|CRS 207 | CRS-207 is a vaccine comprised of a live-attenuated strain of Listeria monocytogenes engineered to express human mesothelin, which induces anti-tumor immune response towards mesothelin-positive tumor cells (PMID: 22147941, PMID: 32273276, PMID: 32132105). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02243371 | Phase II | GVAX pancreatic cancer vaccine CRS-207 Cyclophosphamide | GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab | Completed | USA | 0 |
NCT02575807 | Phase Ib/II | Epacadostat CRS-207 | Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer | Terminated | USA | CAN | 0 |